Clinical Trials Logo

Eye Diseases clinical trials

View clinical trials related to Eye Diseases.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06390644 Active, not recruiting - Dry Eye Clinical Trials

Effect of Periorbital Massage on Dry Eye Disease

Start date: October 1, 2023
Phase: N/A
Study type: Interventional

This randomized controlled trial aims to investigate the efficacy of periorbital massage therapy in alleviating symptoms and improving clinical outcomes in patients diagnosed with dry eye disease.

NCT ID: NCT06269393 Active, not recruiting - Clinical trials for Thyroid Associated Ophthalmopathy

A Study of IBI311 in Subjects With Steroid-resistant, Thyroid Associated Ophthalmopathy

Start date: January 1, 2024
Phase: Phase 3
Study type: Interventional

This is an exploratory study of the efficacy and safety of IBI311, a modified anti-IGF-1R antibody, in patients with steroid-resistant, thyroid associated ophthalmopathy (TAO). This study includes two stages. Stage I is a single-center, single-arm, open-label clinical study designed to evaluate the safety and tolerability of IBI311 in subjects with TAO. Approximately 10 subjects meeting the study eligibility criteria will be enrolled. Stage II is a single-center, randomized, double-masked, placebo-controlled clinical trial designed to evaluate the efficacy and safety of IBI311 in subjects with steroid-resistant TAO. Approximately 54 subjects meeting the study eligibility criteria will be randomly assigned to IBI311 or placebo on day 1 (D1) in a 2:1 ratio stratified by disease activity.

NCT ID: NCT06208384 Active, not recruiting - Dry Eye Disease Clinical Trials

Topical Statin Eye Drop in the Management of the Dry Eye

Start date: January 4, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

In the first stage, to evaluate the safety of the topical medication produced by Sina Pharmaceuticals, this medication is experimentally tested on 10 volunteer patients. If no side effects occur, eligible patients are enrolled in the study after examination by a specialist. The second stage is a randomized, double-blind clinical trial, during which selected patients are randomly assigned to the control and intervention groups. For patients in the intervention group, in addition to standard treatment, including eyelid hygiene and the use of artificial tears, a topical drop of Atorvastatin (50 microM) will be administered, one drop eight times a day in both eyes. In the control group, a placebo will be used in the same manner. The patients will be unaware of their assigned group. Clinical examinations, including Schirmer's test, tear breakup time, fluorescein staining, and completion of the dry eye syndrome questionnaire and dry eye questionnaire, will be conducted before and after the intervention to assess the level of eye dryness.

NCT ID: NCT06069752 Active, not recruiting - Clinical trials for Ophthalmological Disorder

Positional Stability and Refractive Behaviour After Implantation of an IOL After Cataract Surgery

Start date: March 8, 2022
Phase:
Study type: Observational

The newest generation Lucia 621 has a step vault design that is claimed to provide excellent positional and refractive predictability. In order to explore the positional stability, anterior chamber depth stability is examined as marker for haptic buckling comparing positional behaviour after conventional and femtosecond-laser assisted cataract surgery.

NCT ID: NCT05896670 Active, not recruiting - Dry Eye Disease Clinical Trials

Safety and Efficacy of Licaminlimab Ophthalmic Suspension for the Treatment of Dry Eye Disease

RELIEF
Start date: November 29, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to learn about licaminlimab (OCS-02) in the treatment of dry eye disease. The main question it aims to answer is if licaminlimab ophthalmic suspension is more effective than vehicle in treating signs of dry eye disease.

NCT ID: NCT05814757 Active, not recruiting - Dry Eye Syndromes Clinical Trials

OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED)

Start date: May 11, 2023
Phase: Phase 2
Study type: Interventional

To assess the efficacy and safety of OTX-DED for the short-term treatment of the symptoms of DED

NCT ID: NCT05776121 Active, not recruiting - Thyroid Eye Disease Clinical Trials

Study of ZB001 in Chinese Patients With Thyroid Eye Disease

Start date: May 10, 2023
Phase: Phase 1
Study type: Interventional

The investigational drug, ZB001 is a humanized IgG1κ monoclonal antibody targeting human IGF-1R. The study is designed to evaluate the efficacy, safety, tolerability, and pharmacokinetics(PK)/pharmacodynamics (PD) profile of ZB001 in Chinese patients with Thyroid Eye Disease.

NCT ID: NCT05728762 Active, not recruiting - Myopia Clinical Trials

Light Emitting Diodes With a Continuous Spectrum of 430-780nm for Myopia Prevention

Start date: February 22, 2023
Phase: N/A
Study type: Interventional

The purpose of this clinical trial is to evaluate the effect of light-emitting diodes (LEDs) with a continuous spectrum of 430-780 nm for lighting in the classroom on myopia prevention among children in Grades 2 and 3.

NCT ID: NCT05618730 Active, not recruiting - Dry Eye Clinical Trials

Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B

Start date: September 29, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this interventional study is to assess safety, patient tolerability, plug retention rate, and preliminary efficacy in improving the symptoms of Dry Eye Disease (DED) of EXP-TC tacrolimus releasing punctal plug. The main questions it aims to answer are: 1. The safety of using EXP-TC plug following all study adverse events 2. The number of patients with Adverse Events related to the us of EXP-LP plug 3. The number of patients discontinuing the study due to plug discomfort 4. The total patients with plugs remained during the 3-months study duration from plug insertion 5. Exploratory: change from baseline in the study eye to follow-up visits in various Dryness clinical measurements. The change of measurements from baseline will also be compared between the study and fellow control eye (receiving artificial tears only, 0.15% sodium hyaluronate).

NCT ID: NCT05276063 Active, not recruiting - Eye Diseases Clinical Trials

A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

LIDS
Start date: July 1, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

The overall objective is to study the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twice daily (BID) vs. placebo, at 24 weeks in the treatment of subjects with active, moderate to severe thyroid eye disease (TED).